STELARA 90 MG/ML SYRINGE
FDA nonproprietary name: ustekinumab
For 1 mL
Pharmacies pay
$29,792.79 filed
1 × $29,792.78667 per ML
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$26,534.27 filed
1 × $26,534.26669 per ML, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
0.89× estimated
Medicare paid 11% less than pharmacies pay.
Part D averages every strength and form sold under “Stelara*” / “Ustekinumab” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$34,266.71 estimated
$29,792.79 + $4,468.92 (15%) + $5.00 fee per fill = $34,266.71
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
STELARA 90 MG/ML SYRINGE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as ustekinumab, under the trade name “STELARA”.
FDA gives its dosage form as injection, solution and its route as subcutaneous.
The labeler, the company named on the label, is Janssen Biotech, Inc.
FDA lists it under 2 Established Pharmacologic Classes: Interleukin-12 Antagonist and Interleukin-23 Antagonist.
The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 57894-0061-03.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $29,792.79 for 1 mL (1 × $29,792.78667 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.
What NADAC measures · NADAC explanation codes
The NDC
- 57894-0061-03 · Janssen Biotech, Inc. · $29,792.78667 per ML · eff. 2026-09-23 filed
Other strengths, forms and brands
3 other products in the NADAC file share the FDA nonproprietary name ustekinumab with STELARA 90 MG/ML SYRINGE.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| STELARA 45 MG/0.5 ML SYRINGE | $29,874.448 per ML filed | $26,534.26669 per ML filed |
| STELARA 90 MG/ML SYRINGE this page | $29,792.78667 per ML filed | $26,534.26669 per ML filed |
| YESINTEK 45 MG/0.5 ML SYRINGE | $2,855.572 per ML filed | $277.20 per ML derived |
| YESINTEK 90 MG/ML SYRINGE | $2,902.87833 per ML filed | $277.20 per ML derived |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)
Compared with its class
Its NADAC price is $29,792.78667 per ML filed.
Of the 4 other products in FDA’s Interleukin-12 Antagonist class priced per ML, 1 has a higher middle NADAC price and 3 a lower one. The one in the middle is YESINTEK 90 MG/ML SYRINGE, at $2,902.87833 per ML filed (eff. 2026-09-23).
Of the 10 other products in FDA’s Interleukin-23 Antagonist class priced per ML, 1 has a higher middle NADAC price and 9 a lower one. The one in the middle is TREMFYA 100 MG/ML PEN, at $14,620.06917 per ML filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
Medicare Part D paid $26,534.27 for 1 mL, at an average of $26,534.26669 per ML in 2024 (2024-01-01 to 2024-12-31) for “Stelara*” and “Ustekinumab”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 132,865 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 1 mL? Is it lower than what I would pay through my insurance?
- How much is in the package I am getting? This page uses 1 mL; your package may hold a different amount.
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for STELARA 90 MG/ML SYRINGE labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Stelara* / Ustekinumab: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's ML. Joined on brand name. *: CMS says this average reflects multiple routes of administration, which may have different unit prices. All 2 NADAC NDCs the name join matched to it have an FDA route including SUBCUTANEOUS.
- Why does this page start at 1 mL?
- NADAC prices this product per ML. The FDA NDC Directory’s package description gives 1 mL in one package for this product’s NDC (“1 SYRINGE in 1 CARTON (57894-061-03) / 1 mL in 1 SYRINGE”), so the card starts at one package: 1 ML. Change it to match your prescription.